摘要
目的探讨二甲双胍治疗肥胖伴高胰岛素血症非糖尿病儿童的有效性和安全性。方法将22例肥胖伴高胰岛素血症的非糖尿病患儿分为治疗组(二甲双胍+饮食控制+锻炼)和对照组(饮食控制+锻炼)。观察二组治疗前和治疗6个月后体质量指数(BMI)、胰岛素抵抗指数(HOMA-IR)、空腹血糖(FPG)和空腹胰岛素(FINS)、餐后2 h血糖和胰岛素(2 h PG和INS),及血浆总胆固醇(TC)和三酰甘油(TG)的变化,观察治疗组治疗期间不良反应。结果治疗组治疗前后BMI、TC、FINS、HOMA-IR比较差异有显著性(P<0.05,0.001);对照组治疗前后BMI比较差异有显著性(P<0.05),其余各项指标比较均无显著差异(Pa>0.05)。治疗组和对照组治疗前各项指标比较差异均无显著性(Pa>0.05),治疗6个月后FINS、HOMA-IR比较差异有显著性(Pa<0.001)。治疗组治疗初期有腹部不适、腹泻3例(27%),无其他不适症状,治疗3、6个月随访肝肾功能均正常。结论二甲双胍用于治疗肥胖伴高胰岛素血症非糖尿病儿童可明显降低空腹胰岛素,改善胰岛素抵抗。
Objective To explore the efficacy and safety of mefformin therapy on obese nondiabetic children with hyperinsulinemia. Methods Twenty -two obese nondiabetic children with hyperinsulinemia were divided into two groups：control group （dietary counseling and exercise） and treatment group （ dietary counseling and exercise combined with mefformin）. The changes of body mass index（BMI） ,fasting glucose （ FPG）, fasting insulin （ FINS ） , insulin resistance （ HOMA - IR） ,2 h PG, 2 h INS, total cholesterol （ TC ） and triglyceride （TG） , before and after treatment were determined, and the findings were compared and analyzed. Results After treatment,there were significant differences in BMI,TC, FINS,HOMA- IR levels （P 〈 0. 05,0. 001 ） in treatment group , while FINS and HOMA -IR levels in treatment group were significantly lower than those in control group（ Pa 〈 0. 001 ）. However, before and after treatment, each target in control group had no changed obviously （Pa 〉 0. 05 ）, except the B MI （P 〈 0. 05 ）. Three patients （27%） presented transient abdominal discomfort or diarrhea. No changes in liver and renal function tests were found in treatment group before and after treatment. Conclusions Mefformin is helpful in reducing the fasting insulin and insulin resistance index. It is safe and can be used in treatment of obese nondiabetic children with hyperinsulinemia.
出处
《实用儿科临床杂志》
CAS
CSCD
北大核心
2007年第8期624-625,共2页
Journal of Applied Clinical Pediatrics
